Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €56.00 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:16 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by ABBVIE INC (ABBV) in the last 6 months

Announced 03/4/15
19.86B for Pharmacyclics Inc.
Merger/Acquisition

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Pharmacyclics Inc. (NasdaqGS:PCYC) from ProQuest Investments and others for $19.8 billion in cash and stock on March 4, 2015. Under the terms of the agreement, AbbVie will acquire all of the outstanding shares of Pharmacyclics through a tender offer, followed by a second-step merger. In the tender offer, AbbVie will acquire all of the outstanding shares of Pharmacyclics' common stock for $261.25 per share, ...
Read More


ABBV's price was unchanged after the transaction was announced on 03/4/15.
Investor / Buyer
AbbVie Inc.
Creditor / Lender
ProQuest Investments
Financial Advisor
Centerview Partners LLC
J.P. Morgan Securities LLC
Legal Advisor
Wilson, Sonsini, Goodrich & Rosati
 
Announced 11/20/14
Manufacturing Site in Tuas Biomedical Park
Merger/Acquisition

AbbVie Inc. (NYSE:ABBV) acquired manufacturing site in Tuas Biomedical Park on November 20, 2014.


ABBV's price was unchanged after the transaction was announced on 11/20/14.
Investor / Buyer
AbbVie Inc.
 
Announced 10/20/14
5.00B for AbbVie Inc.
Buyback

AbbVie Inc. (NYSE:ABBV) announces a share repurchase program. Under the program, the company will repurchase up to $5,000 million of the company's outstanding common stock. This authorization permits shares to be repurchased in open market or private transactions. The program has no time limit and may be discontinued at any time. The share repurchase authorization is expected to be completed over the next several years. The Board of Directors of AbbVie Inc. has authorized ...
Read More


ABBV's price was unchanged after the transaction was announced on 10/20/14.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:FP €56.00 EUR 0.00

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.50 USD -0.94
Amgen Inc $154.88 USD -4.72
AstraZeneca PLC 4,416 GBp -71.00
Eli Lilly & Co $68.41 USD -2.18
Novo Nordisk A/S kr321.10 DKK +3.10
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 51.9x
Price/Sales 4.5x
Price/Book 51.9x
Price/Cash Flow 51.1x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.